NCT03375632View on ClinicalTrials.gov

Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

May 29, 2018

Study Completion Date

June 5, 2018

Conditions
Hyperuricemia With or Without Gout
Interventions
DRUG

FYU-981

Oral daily dosing for 14 weeks

Trial Locations (1)

Unknown

Mochida Investigational sites, Tokyo

Sponsors

Collaborators (1)

Fuji Yakuhin Co., Ltd.
All Listed Sponsors
collaborator

Fuji Yakuhin Co., Ltd.

INDUSTRY

lead

Mochida Pharmaceutical Company, Ltd.

INDUSTRY

NCT03375632 - Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types) | Biotech Hunter | Biotech Hunter